Literature DB >> 33474621

Letter to the editors: comment on "Emerging themes in idiopathic intracranial hypertension".

Simona Toscano1, Mario Zappia2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33474621     DOI： 10.1007/s00415-021-10401-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

Review 1.  Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression?

Authors:  Roberto De Simone; Angelo Ranieri; Chiara Fiorillo; Leonilda Bilo; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2010-02-25       Impact factor: 3.307

Review 2.  Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine.

Authors:  Roberto De Simone; Angelo Ranieri; Mattia Sansone; Enrico Marano; Cinzia Valeria Russo; Francesco Saccà; Vincenzo Bonavita
Journal:  Neurol Sci       Date:  2019-05       Impact factor: 3.307

Review 3.  An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management.

Authors:  Simona Toscano; Salvatore Lo Fermo; Ester Reggio; Clara Grazia Chisari; Francesco Patti; Mario Zappia
Journal:  J Neurol       Date:  2020-05-27       Impact factor: 4.849

4.  Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.

Authors:  Deborah I Friedman; Grant T Liu; Kathleen B Digre
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

5.  A comparison of idiopathic intracranial hypertension with and without papilledema.

Authors:  Kathleen B Digre; Beau K Nakamoto; Judith E A Warner; Wendy J Langeberg; Susan K Baggaley; Bradley J Katz
Journal:  Headache       Date:  2009-02       Impact factor: 5.887

6.  Emerging themes in idiopathic intracranial hypertension.

Authors:  Olivia Grech; Susan P Mollan; Benjamin R Wakerley; Zerin Alimajstorovic; Gareth G Lavery; Alexandra J Sinclair
Journal:  J Neurol       Date:  2020-07-22       Impact factor: 4.849
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.